Synthesis and Structure−Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF1) An

详细信息    查看全文

• 作者：Paul J. Gilligan ; Todd Clarke ; Liqi He ; Snjezana Lelas ; Yu-Wen Li ; Karen Heman ; Lawrence Fitzgerald ; Keith Miller ; Ge Zhang ; Anne Marshall ; Carol Krause ; John F. McElroy ; Kathyrn Ward ; Kim Zeller ; Har
• 刊名：Journal of Medicinal Chemistry
• 出版年：2009
• 出版时间：May 14, 2009
• 年：2009
• 卷：52
• 期：9
• 页码：3084-3092
• 全文大小：155K
• 年卷期：v.52,no.9(May 14, 2009)
• ISSN：1520-4804

文摘

This report describes the syntheses and structure−activity relationships of 8-(substituted pyridyl)pyrazolo[1,5-a]-1,3,5-triazine corticotropin releasing factor receptor-1 (CRF₁) receptor antagonists. These CRF₁ receptor antagonists may be potential anxiolytic or antidepressant drugs. This research resulted in the discovery of compound 13-15, which is a potent, selective CRF₁ antagonist (hCRF₁ IC₅₀ = 6.1 ± 0.6 nM) with weak affinity for the CRF-binding protein and biogenic amine receptors. This compound also has a good pharmacokinetic profile in dogs. Analogue 13-15 is orally effective in two rat models of anxiety: the defensive withdrawal (situational anxiety) model and the elevated plus maze test. Analogue 13-15 has been advanced to clinical trials.